Dr. Forte Soto is an MHRA-accredited Principal Investigator with over 25 years of experience in clinical practice and research. As Director of Safety Human Pharmacology at Parexel’s London Early Phase Clinical Unit, he has led or contributed to more than 200 Phase I/II studies, including first-in-human trials, drug-drug interaction studies, bioequivalence, thorough QT, biosimilars, and proof-of-concept research.
His therapeutic expertise spans CNS, immunology, cardiovascular, metabolism, respiratory, and dermatology. Dr. Forte Soto holds a medical degree from the University of Central Venezuela, an MSc in Clinical Pharmacology from the University of Aberdeen, and a DPhil in Clinical Pharmacology from the University of London. He completed postdoctoral training at the William Harvey Research Institute and is a Fellow of the Faculty of Pharmaceutical Medicine (FFPM).